Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's New Chief Medical Officer Levi Garraway Brings Deep Cancer Genomics Expertise

Executive Summary

CMO Sandra Horning will retire at the end of the year, to be succeeded by Lilly's former senior VP of oncology R&D on 1 October.

You may also be interested in...



Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

Bucking Biosimilar Threat, Roche Sees Further Growth

Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.

Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi

Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC125726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel